The FDA issued a warning to ImmunityBio over what it described as false and misleading claims about Anktiva in a TV advertisement and a podcast. The agency said the messaging created a misleading impression that Anktiva can cure or prevent all cancers, including omission of key safety and use requirements. According to the warning letter, Anktiva must be used in combination with a vaccine, but risks were allegedly downplayed in the ad and not addressed in the podcast. The FDA also said both pieces suggested patients treated with Anktiva would be “cancer free,” a claim the agency said was not supported by clinical studies. The enforcement action raises attention on biotech commercialization compliance risk—particularly when promotional content implies broader indications or outcomes than trial evidence supports—and adds scrutiny for ongoing promotional practices around oncology products.